Enzo Biochem Inc. (ENZ) Hits New 52-week High During January 12 Session

Equities Staff  |

Enzo Biochem Inc. (ENZ) hit a new 52-week high yesterday, reaching a peak of $5.09 after opening at $4.95 and closing at $4.78 for a move of -2.05%.

Hitting a new 52-week high is a notable milestone for any company, and it can mean a trading opportunity on either the long or short side, depending on one's perspective. Some view a company hitting its highest price in a year as a sign of momentum and think it means it's time to buy in. Others, though, tend to interpret a new 52-week high as likely signaling the end of a strong run, with the stock peaking out before a period of decline.

However one plays it, it’s often a critical moment for any stock and should be noted by investors.

The new 52-week high came on a volume of 163,320 for a stock that has a float of 46.07 million shares and an average daily volume of $162,119. The day's trading means the company's market cap is now at $220.21 million and it has a 50-day SMA of $4.47 and a 200-day SMA of $3.39.

Enzo Biochem Inc. now has a P/E ratio of 34.9.

For a complete fundamental analysis analysis of Enzo Biochem Inc., check out Equities.com’s Stock Valuation Analysis report for ENZ. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

Enzo Biochem Inc is engaged in research, development, manufacturing and marketing of health care products, platforms and services. The Company's business segments are Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics.

Enzo Biochem Inc. is based out of New York, NY and has some 483 employees. Its CEO is Elazar Rabbani.

Enzo Biochem Inc. is also a component of the Russell 2000 Index, which is an invaluable tool for any small-cap investor. Consisting of the smaller 2,000 publicly traded companies of the 3,000 largest companies in America by market cap (which combine to make the broader Russell 3000 index), the Russell 2000 gives the most comprehensive snapshot of the small-cap market of any index out there.

What's more, the Russell 2000 is maintained by Russell Investments, a company committed to using rules-based methodologies to construct unbiased indices that differ from the committee-selected Dow Jones Industrial Average or S&P 500.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


What Is Petrolithium?

MGX Minerals explains the advantages of petrolithium and how they are helping to solve future problems today.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.